AzTrials
AzTrials

Bronchopulmonary DysplasiaNCT00005289

Risk Factors in Bronchopulmonary Dysplasia (Newborn Lung Project)

An observational study of Bronchopulmonary Dysplasia and Lung Diseases, run by University of Wisconsin, Madison.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

To investigate risk factors in bronchopulmonary dysplasia (BPD) and to elucidate the relationship between BPD, acute lung disease severity, respiration-related variables, water balance, nutrition, familial predisposition, and environmental, pregnancy, and delivery parameters. Read more about this study

Who is it for?
Ages Up to 100 years
How many people
2,202 participants
Where
No sites listed yet
Study dates
Jul 1987to Jul 2008
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages Up to 100 years
  • All sexes
  • No healthy volunteers
  • Child, Adult, Older adult
  • Birthweight less than 1500 grams

About this study

To investigate risk factors in bronchopulmonary dysplasia (BPD) and to elucidate the relationship between BPD, acute lung disease severity, respiration-related variables, water balance, nutrition, familial predisposition, and environmental, pregnancy, and delivery parameters.

Read the detailed description

BACKGROUND:

Despite many improvements in neonatal intensive care during the decade from 1977 to 1987, infant respiratory distress syndrome remained a major public health problem. Increasing survival among premature infants led to the emergence of BPD as the major chronic respiratory disorder of infancy. The vast majority of BPD occurs in very low birth weight infants weighing less than 1,500 grams.

Although the incidence of low birth weight births declined from 1977 to 1987, the rate of very low birth weight births remained unchanged. These infants had a relative risk of neonatal death almost 200 times greater than full-term infants. Among survivors, eight percent had evidence of chronic pulmonary disease at forty weeks of age. The Institute of Medicine reported that very low birth weight infants who survived to one year of age were hospitalized for an average of 57 days after birth versus 3.5 days for full-term infants. Up to forty percent of these infants would be re-hospitalized almost two times for an average of 16 days versus 8.7 percent of normal birth weight infants for an average of 8 days.

DESIGN NARRATIVE:

The study had a nested case-control design. In the first year of the project, the diagnosis of BPD was standardized and a scoring system developed for grading the severity of the disease. Baseline data were collected on very low birth weight neonates admitted to seven participating neonatal intensive care units. Maternal interviews were conducted for neonates surviving seven days. The purpose of the interview was to collect information which m;ight be related to a predisposition to BPD, respiratory distress syndrome, or prematurity. Specific areas addressed included familial diseases in general and respiratory diseases in particular, familial patterns of prematurity, pregnancy and birth history, circumstances surrounding delivery, environmental exposures, health habits such as smoking, and socioeconomic variables. Severity scoring and diagnosis of the infants were based on the hospital log and routine x-rays. Final analysis compared infants with BPD to those without BPD, controlling for confounders and placing special emphasis on interaction effects. Full-term neonates served as controls.

The study was renewed in 1994 in order to re-contact at age 4-5, an existing cohort of 634 children with birth weight below 1501 grams. This cohort was unique in being representative of all very low birth weight survivors in a geographic area, and in being born during a time period of rapid advances in neonatal care (Aug 1, 1988-June 30, 1991). These children were enrolled at admission to any of 6 neonatal intensive care units (NlCUs) in Wisconsin and Iowa, and had extensive data already collected. The re-contact consisted of a telephone interview with parents, including standardized functional assessment. Information on health care and major diagnoses was also collected and verified by medical record abstracting. Information on socioeconomic and insurance status was obtained. The study responded to a need for global assessment of very low birth weight survivors, since most previous studies in the United States focused on specific morbidity outcomes. Special features of already existing data included scoring of respiratory distress syndrome and bronchopulmonary dysplasia severity with new validated severity indices, baseline family health history information and perinatal data. The cohort also spanned the time period from before general availability of exogenous surfactant to its availability as an investigational new drug (8/1/89) and availability for marketing (8/1/90). The study therefore provided an opportunity to investigate the long term effectiveness of this new therapy in an unselected NlCU population. The data were analyzed to describe the overall status of the cohort, to examine trends in outcomes across the time period, to find predictors of outcome among the neonatal and socioeconomic indicators and to investigate whether there was variability between centers.

The study was renewed in 1998 to continue follow-up of the cohort of 403 very low birth weight neonatal care survivors, born during August 1988-June1991. The time period of birth includes the approval dates for surfactant therapy. Hence, the first children to be treated with surfactant in general neonatal intensive care units (NICU) are now entering school age, providing an opportunity to evaluate school performance and to assess true chronicity of respiratory limitations. A large NICU and follow-up data base on the cohort contains extensive baseline assessment of respiratory disease, neonatal treatments and diagnoses, as well as functional assessment, health status and health care utilization at ages 4-6. The addition of data up to age 10 will confirm or dispute findings that functional outcome may be lower among children born after surfactant was released for marketing, and that the prevalence of long-term respiratory problems has remained the same. The new outcome data to be collected include school performance from school records and parent and teacher questionnaires, respiratory function by peak flow meters and respiratory symptoms and medications by parent interviews and questionnaires.

The study was renewed in 2002 to continue research in the evolving risk factors and outcomes of bronchopulmonary dysplasia (BPD) and other neonatal conditions of very low birth weight (VLBW, < 1500g) infants and children. The renewal will comprehensively document the neonatal and early childhood course and outcomes of all VLBW births in Wisconsin occurring during the calendar years 2003 and 2004 (800-850 per year), using established methodology with added risk factor information to examine currently proposed inflammatory hypotheses of BPD etiology. The study will also implement and validate new diagnostic criteria for the severity of BPD developed by a recent NIH workshop.

Medical subject headings
Bronchopulmonary Dysplasia, Lung Diseases, Respiratory Distress Syndrome

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

Study groups in NCT00005289
Study groupRoleWhat they receive
1988-1991Not described
2003-2004Not described

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted26 May 2000 (estimated)
  2. Study startJul 1987
  3. Primary completionJul 2008
  4. Study completionJul 2008

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Prospective
Enrolment
2,202 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT00005289
Sponsor's protocol ID
1997-152
Other IDs
R01HL038149, 1997-152, 2002-209
Status last verified
Jul 2019
First submitted
25 May 2000
Last updated
17 Jul 2019
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No

Publications

  • Farrell ET, Bates ML, Pegelow DF, Palta M, Eickhoff JC, O'Brien MJ, Eldridge MW. Pulmonary Gas Exchange and Exercise Capacity in Adults Born Preterm. Ann Am Thorac Soc. 2015 Aug;12(8):1130-7. doi: 10.1513/AnnalsATS.201410-470OC.

    PubMed 26053283
  • Palta M, Gabbert D, Fryback D, Widjaja I, Peters ME, Farrell P, Johnson J. Development and validation of an index for scoring baseline respiratory disease in the very low birth weight neonate. Severity Index Development and Validation Panels and Newborn Lung Project. Pediatrics. 1990 Nov;86(5):714-21.

    PubMed 2235225
  • Palta M, Gabbert D, Weinstein MR, Peters ME. Multivariate assessment of traditional risk factors for chronic lung disease in very low birth weight neonates. The Newborn Lung Project. J Pediatr. 1991 Aug;119(2):285-92. doi: 10.1016/s0022-3476(05)80746-2.

    PubMed 1861218
  • Palta M, Weinstein MR, McGuinness G, Gabbert D, Brady W, Peters ME. A population study. Mortality and morbidity after availability of surfactant therapy. Newborn Lung Project. Arch Pediatr Adolesc Med. 1994 Dec;148(12):1295-301. doi: 10.1001/archpedi.1994.02170120057009.

    PubMed 7951809
  • Palta M, Sadek-Badawi M, Evans M, Weinstein MR, McGuinnes G. Functional assessment of a multicenter very low-birth-weight cohort at age 5 years. Newborn Lung Project. Arch Pediatr Adolesc Med. 2000 Jan;154(1):23-30.

    PubMed 10632246
  • Evans M, Palta M, Sadek M, Weinstein MR, Peters ME. Associations between family history of asthma, bronchopulmonary dysplasia, and childhood asthma in very low birth weight children. Am J Epidemiol. 1998 Sep 1;148(5):460-6. doi: 10.1093/oxfordjournals.aje.a009671.

    PubMed 9737558
  • Palta M, Sadek M, Lim TS, Evans M, McGuinness G. Association of tocolytic therapy with antenatal steroid administration and infant outcomes. Newborn Lung Project. Am J Perinatol. 1998 Feb;15(2):87-92. doi: 10.1055/s-2007-993904.

    PubMed 9514131
  • Palta M, Sadek M, Barnet JH, Evans M, Weinstein MR, McGuinness G, Peters ME, Gabbert D, Fryback D, Farrell P. Evaluation of criteria for chronic lung disease in surviving very low birth weight infants. Newborn Lung Project. J Pediatr. 1998 Jan;132(1):57-63. doi: 10.1016/s0022-3476(98)70485-8.

    PubMed 9470001
  • Palta M, Sadek M, Gabbert D, Brady W, Weinstein MR, McGuinness G, Peters ME. The relation of maternal complications to outcomes in very low birthweight infants in an era of changing neonatal care. Am J Perinatol. 1996 Feb;13(2):109-14. doi: 10.1055/s-2007-994303.

    PubMed 8672182
  • Weinstein MR, Peters ME, Sadek M, Palta M. A new radiographic scoring system for bronchopulmonary dysplasia. Newborn Lung Project. Pediatr Pulmonol. 1994 Nov;18(5):284-9. doi: 10.1002/ppul.1950180504.

    PubMed 7898966
  • Palta M, Sadek-Badawi M, Sheehy M, Albanese A, Weinstein M, McGuinness G, Peters ME. Respiratory symptoms at age 8 years in a cohort of very low birth weight children. Am J Epidemiol. 2001 Sep 15;154(6):521-9. doi: 10.1093/aje/154.6.521.

    PubMed 11549557
  • Hagen EW, Palta M, Albanese A, Sadek-Badawi M. School achievement in a regional cohort of children born very low birthweight. J Dev Behav Pediatr. 2006 Apr;27(2):112-20. doi: 10.1097/00004703-200604000-00005.

    PubMed 16682874
  • Palta M, Sadek-Badawi M, Madden K, Green C. Pulmonary testing using peak flow meters of very low birth weight children born in the perisurfactant era and school controls at age 10 years. Pediatr Pulmonol. 2007 Sep;42(9):819-28. doi: 10.1002/ppul.20662.

    PubMed 17659600
  • Hagen EW, Sadek-Badawi M, Albanese A, Palta M. A comparison of Wisconsin neonatal intensive care units with national data on outcomes and practices. WMJ. 2008 Nov;107(7):320-6.

    PubMed 19180870
  • Hagen EW, Sadek-Badawi M, Carlton DP, Palta M. Permissive hypercapnia and risk for brain injury and developmental impairment. Pediatrics. 2008 Sep;122(3):e583-9. doi: 10.1542/peds.2008-1016.

    PubMed 18762492

Questions about this trial

What is this clinical trial studying?

An observational study of Bronchopulmonary Dysplasia and Lung Diseases, run by University of Wisconsin, Madison.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 17 Jul 2019. Status can change between updates, so confirm with the study contact before making plans.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT00005289, which also lists 27 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 17 Jul 2019.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in